WO2000047568A3 - Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate - Google Patents
Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate Download PDFInfo
- Publication number
- WO2000047568A3 WO2000047568A3 PCT/US2000/002503 US0002503W WO0047568A3 WO 2000047568 A3 WO2000047568 A3 WO 2000047568A3 US 0002503 W US0002503 W US 0002503W WO 0047568 A3 WO0047568 A3 WO 0047568A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzothiazepines
- treatment
- hyperlipidemic diseases
- hyperlipidemic
- diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical class S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 title 1
- NGBHIADNEOTIAL-UHFFFAOYSA-N 1$l^{6},2-benzothiazepine 1,1-dioxide Chemical class O=S1(=O)N=CC=CC2=CC=CC=C12 NGBHIADNEOTIAL-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020017010201A KR20020000139A (ko) | 1999-02-12 | 2000-02-10 | 회장 담즙산 수송 및 타우로콜산염 흡수의 억제제로서의활성을 보유하는 신규한 1,2-벤조티아제핀 |
IL14471600A IL144716A0 (en) | 1999-02-12 | 2000-02-10 | Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
JP2000598488A JP2002536440A (ja) | 1999-02-12 | 2000-02-10 | 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規1,2−ベンゾチアゼピン |
EP00915720A EP1155007A2 (fr) | 1999-02-12 | 2000-02-10 | Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate |
AU36946/00A AU3694600A (en) | 1999-02-12 | 2000-02-10 | Novel 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
CA002362147A CA2362147A1 (fr) | 1999-02-12 | 2000-02-10 | Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11993399P | 1999-02-12 | 1999-02-12 | |
US60/119,933 | 1999-02-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000047568A2 WO2000047568A2 (fr) | 2000-08-17 |
WO2000047568A3 true WO2000047568A3 (fr) | 2000-12-14 |
Family
ID=22387268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/002503 WO2000047568A2 (fr) | 1999-02-12 | 2000-02-10 | Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1155007A2 (fr) |
JP (1) | JP2002536440A (fr) |
KR (1) | KR20020000139A (fr) |
CN (1) | CN1195748C (fr) |
AU (1) | AU3694600A (fr) |
CA (1) | CA2362147A1 (fr) |
HU (1) | HUP0105409A3 (fr) |
IL (1) | IL144716A0 (fr) |
WO (1) | WO2000047568A2 (fr) |
ZA (1) | ZA200106252B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11844822B2 (en) | 2014-06-25 | 2023-12-19 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) * | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
BR0311767A (pt) | 2002-06-11 | 2005-03-08 | Wyeth Corp | Compostos inibidores de sulfonamida substituìda da produção de beta amilóide, suas composições e usos |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
ATE531701T1 (de) * | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
KR20070026392A (ko) * | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
SG190433A1 (en) | 2010-11-08 | 2013-06-28 | Albireo Ab | A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder |
DK2637668T3 (en) | 2010-11-08 | 2016-08-29 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
MX363161B (es) | 2011-10-28 | 2019-03-13 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica. |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
KR20230152818A (ko) | 2013-03-15 | 2023-11-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제 |
CA2907214A1 (fr) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Inhibiteurs de recyclage d'acide biliaire pour le traitement de l'sophage de barrett et du reflux gastrosophagien pathologique |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
EP3012252A1 (fr) | 2014-10-24 | 2016-04-27 | Ferring BV | Formes crystallines d'Elobixibat |
RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
WO2019032026A1 (fr) | 2017-08-09 | 2019-02-14 | Albireo Ab | Granules de cholestyramine, formulations orales de cholestyramine et leur utilisation |
JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100113A1 (fr) | 2018-06-05 | 2019-12-12 | Albireo Ab | Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
WO2019245448A1 (fr) | 2018-06-20 | 2019-12-26 | Albireo Ab | Modifications cristallines d'odévixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
JP7504110B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
WO2020161217A1 (fr) | 2019-02-06 | 2020-08-13 | Albireo Ab | Composés de benzothiadiazépine et leur utilisation en tant que modulateurs d'acide biliaire |
BR112021015799A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
WO2021110887A1 (fr) | 2019-12-04 | 2021-06-10 | Albireo Ab | Composés de benzothiazépine et leur utilisation en tant que modulateurs de l'acide biliaire |
JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
WO2021110884A1 (fr) | 2019-12-04 | 2021-06-10 | Albireo Ab | Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs d'acide biliaire |
AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
JP2023504643A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
CA3158276A1 (fr) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Composes de benzothia(di)azepine et leur utilisation en tant que modulateurs d'acide biliaire |
JP2023537285A (ja) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
AU2021379076A1 (en) | 2020-11-12 | 2023-06-08 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
EP4255565A1 (fr) | 2020-12-04 | 2023-10-11 | Albireo AB | Composés de benzothia(di)azepine et leur utilisation en tant que modulateurs de l'acide biliaire |
WO2023237728A1 (fr) | 2022-06-09 | 2023-12-14 | Albireo Ab | Traitement de l'hépatite |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005188A1 (fr) * | 1994-08-10 | 1996-02-22 | The Wellcome Foundation Limited | 1,4-benzothiazepine-1,1-dioxydes a action hypolipidemique |
WO1996016051A1 (fr) * | 1994-11-17 | 1996-05-30 | The Wellcome Foundation Limited | Benzothiazepines hypolipidemiantes |
WO1998002432A1 (fr) * | 1996-07-16 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Composes bicycliques pour commander la miction |
WO1998038182A1 (fr) * | 1997-02-28 | 1998-09-03 | Glaxo Group Limited | Derives bicycliques hypolipidemiques |
-
2000
- 2000-02-10 CN CNB008060282A patent/CN1195748C/zh not_active Expired - Fee Related
- 2000-02-10 EP EP00915720A patent/EP1155007A2/fr not_active Ceased
- 2000-02-10 CA CA002362147A patent/CA2362147A1/fr not_active Abandoned
- 2000-02-10 JP JP2000598488A patent/JP2002536440A/ja active Pending
- 2000-02-10 AU AU36946/00A patent/AU3694600A/en not_active Abandoned
- 2000-02-10 WO PCT/US2000/002503 patent/WO2000047568A2/fr not_active Application Discontinuation
- 2000-02-10 IL IL14471600A patent/IL144716A0/xx unknown
- 2000-02-10 HU HU0105409A patent/HUP0105409A3/hu unknown
- 2000-02-10 KR KR1020017010201A patent/KR20020000139A/ko not_active Application Discontinuation
-
2001
- 2001-07-30 ZA ZA200106252A patent/ZA200106252B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005188A1 (fr) * | 1994-08-10 | 1996-02-22 | The Wellcome Foundation Limited | 1,4-benzothiazepine-1,1-dioxydes a action hypolipidemique |
WO1996016051A1 (fr) * | 1994-11-17 | 1996-05-30 | The Wellcome Foundation Limited | Benzothiazepines hypolipidemiantes |
WO1998002432A1 (fr) * | 1996-07-16 | 1998-01-22 | Takeda Chemical Industries, Ltd. | Composes bicycliques pour commander la miction |
WO1998038182A1 (fr) * | 1997-02-28 | 1998-09-03 | Glaxo Group Limited | Derives bicycliques hypolipidemiques |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11844822B2 (en) | 2014-06-25 | 2023-12-19 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
Also Published As
Publication number | Publication date |
---|---|
HUP0105409A2 (hu) | 2002-05-29 |
HUP0105409A3 (en) | 2004-11-29 |
JP2002536440A (ja) | 2002-10-29 |
CN1346351A (zh) | 2002-04-24 |
IL144716A0 (en) | 2002-06-30 |
CN1195748C (zh) | 2005-04-06 |
AU3694600A (en) | 2000-08-29 |
WO2000047568A2 (fr) | 2000-08-17 |
CA2362147A1 (fr) | 2000-08-17 |
KR20020000139A (ko) | 2002-01-04 |
EP1155007A2 (fr) | 2001-11-21 |
ZA200106252B (en) | 2002-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000047568A3 (fr) | Nouvelles benzothiazepines-1,2 presentant une activite d'inhibition de transport d'acide biliaire ileal et d'absorption de taurocholate | |
IL126038A0 (en) | Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them | |
MX9700890A (es) | 1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos. | |
IL162214A0 (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
MX9703546A (es) | Benzotiazepinas hipolipidemicas. | |
IL125735A0 (en) | Pharmaceutical compositions for the treatment of glaucoma | |
NZ505453A (en) | Hypolipidemic benzothiazepine compounds | |
ZA975866B (en) | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases. | |
MY128654A (en) | Liquid pharmaceutical composition containing an erythropoietin derivative | |
NZ247201A (en) | Substituted sulphonylamido- or sulphonamidocarbonyl-pyridine-2-carboxamide derivatives and pharmaceutical compositions | |
MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
IL94819A0 (en) | 11beta-aryl-4-estrene derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same | |
WO1996022305A3 (fr) | Peptides modifies | |
HUP0103832A3 (en) | Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof | |
PL346143A1 (en) | Tan-1057 derivatives | |
MX9704034A (es) | Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso. | |
AU1719392A (en) | Leukotriene b4 antagonist | |
AU7812794A (en) | Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract | |
HUP0200439A2 (en) | Isonipecotamides for the treatment of integrin-mediated disorders, process for their preparation and pharmaceutical compositions containing them | |
ZA929879B (en) | Compositions for the treatment of mammalian diseases. | |
IL110780A0 (en) | Pharmaceutical compositions containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol for the treatment of the common cold | |
AU686084B3 (en) | Pharmaceutical compositions for the treatment of depressive disorders | |
AU5494298A (en) | Pharmaceutical compositions for the treatment of the eye |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00806028.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000915720 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 36946/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/06252 Country of ref document: ZA Ref document number: 200106252 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 144716 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2362147 Country of ref document: CA Ref document number: 2362147 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017010201 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 598488 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2000915720 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017010201 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 2000915720 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000915720 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017010201 Country of ref document: KR |